Over 20 years ago, it was reported that humans treated with anti-ERBB2 antibodies for ERBB2-positive breast cancer, and mice with conditional post-natal deletion of Nrg1, Erbb2, or Erbb4 tyrosine kinase receptors, develop cardiomyopathy1–6. This evidence concerns the gene ERBB2 and breast cancer.